Research programme: anticancer therapeutics - Avalon
Alternative Names: Anticancer therapeutics research programme - Sanofi-Aventis/AvalonLatest Information Update: 19 Aug 2008
At a glance
- Originator Avalon Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 19 Aug 2008 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 21 Dec 2005 The collaboration between Avalon Pharmaceuticals and sanofi-aventis has expired
- 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form sanofi-aventis